These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23512326)

  • 1. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.
    Lund JL; Stürmer T; Sanoff HK; Brookhart A; Sandler RS; Warren JL
    Cancer; 2013 Jun; 119(11):2038-47. PubMed ID: 23512326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.
    Abrams TA; Brightly R; Mao J; Kirkner G; Meyerhardt JA; Schrag D; Fuchs CS
    J Clin Oncol; 2011 Aug; 29(24):3255-62. PubMed ID: 21768462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
    Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of oxaliplatin-based adjuvant chemotherapy in stage II and III colorectal cancer with perforation].
    Onozawa H; Hatano S; Matsuzawa T; Kuwabara K; Ishiguro T; Sobajima J; Kumamoto K; Fukuchi M; Kumagai Y; Baba H; Ishibashi K; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1749-51. PubMed ID: 25731317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
    Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
    Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.
    Green SL; Dawe DE; Nugent Z; Cheung WY; Czaykowski PM
    J Geriatr Oncol; 2019 Jan; 10(1):132-137. PubMed ID: 30104156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
    Laurent M; Des Guetz G; Bastuji-Garin S; Culine S; Caillet P; Aparicio T; Audureau E; Carvahlo-Verlinde M; Reinald N; Tournigand C; Landre T; LeThuaut A; Paillaud E; Canouï-Poitrine F
    Am J Clin Oncol; 2018 Jan; 41(1):73-80. PubMed ID: 26669742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
    Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
    Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Colorectal Cancer Care in the United States: 1990-2010.
    Murphy CC; Harlan LC; Lund JL; Lynch CF; Geiger AM
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26206950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
    Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerability of Oxaliplatin-Based Adjuvant Chemotherapy for Patients with Colorectal Cancer].
    Matsuo H; Nakanishi M; Arita T; Murayama Y; Kuriu Y; Kosuga T; Konishi H; Morimura R; Komatsu S; Shiozaki A; Ikoma H; Ichikawa D; Fujiwara H; Okamoto K; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2112-4. PubMed ID: 26805281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
    Madbouly KM; Hussein AM; Zeid A
    Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.